Apex Biotechnology Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Thomas Y. Shen
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | 10.4% |
| Management average tenure | no data |
| Board average tenure | 6.9yrs |
Recent management updates
Recent updates
Some May Be Optimistic About Apex Biotechnology's (TWSE:1733) Earnings
Nov 21
Apex Biotechnology (TWSE:1733) Will Be Hoping To Turn Its Returns On Capital Around
Aug 06Apex Biotechnology's (TWSE:1733) Conservative Accounting Might Explain Soft Earnings
Mar 21Apex Biotechnology's (TPE:1733) Returns On Capital Not Reflecting Well On The Business
Apr 17Is Apex Biotechnology (TPE:1733) Using Too Much Debt?
Mar 30Is Apex Biotechnology Corp. (TPE:1733) A Good Fit For Your Dividend Portfolio?
Mar 10Is Apex Biotechnology Corp.'s (TPE:1733) Stock On A Downtrend As A Result Of Its Poor Financials?
Feb 17A Look At Apex Biotechnology's (TPE:1733) Share Price Returns
Jan 27
Returns On Capital At Apex Biotechnology (TPE:1733) Paint An Interesting Picture
Jan 06These 4 Measures Indicate That Apex Biotechnology (TPE:1733) Is Using Debt Safely
Dec 16Is Apex Biotechnology Corp.'s (TPE:1733) 4.5% Dividend Worth Your Time?
Nov 22CEO
Thomas Y. Shen
no data
Tenure
Dr. Thomas Y. S. Shen, Ph D serves as Chairman, Chief Executive Officer and General Manager of Apex Biotechnology Corp. Dr. Shen served as Supervisor/Corporate Representative at Sheng Da Venture Capital. D...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | no data | no data | 10.38% NT$ 299.3m | |
| Vice GM | no data | no data | 0.28% NT$ 8.1m | |
| Independent Director | 3.3yrs | no data | no data | |
| Independent Director | no data | no data | no data | |
| Independent Director | 6.9yrs | no data | no data | |
| Independent Director | 6.9yrs | no data | no data |
6.9yrs
Average Tenure
Experienced Board: 1733's board of directors are considered experienced (6.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 08:29 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Apex Biotechnology Corp. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jiahong Liu | E.Sun Securities Investment Consulting Co. Ltd. |
| Ryan Liu | IBTS Investment Consulting Co., Ltd. |
| Zhennan Lee | Jih Sun Securities Investment Consulting Co., Ltd. |